RBC Capital Out Positive on Neumora Therapeutics (NMRA): ' See Compelling Entry Point Ahead of Key 2H24 Catalysts'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $31.00 price target on Neumora Therapeutics (NASDAQ: NMRA).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
